Inclusion Criteria:

          -  One prior resection of GBM or MRI evidence of solid tumor CNS metastasis

          -  All GBM and NSLC metastases must be ALK+

          -  Eastern Cooperative Oncology Group performance status ≤2

          -  Archival tumor tissue block available for research use

          -  Ability to understand written informed consent

          -  Recovery from toxicities related to prior anticancer therapies to ≤ grade 2 (CTCAE v
             4.03). Exception: patients with any grade alopecia

          -  The following lab criteria are met:

               -  Absolute neutrophil count ≥ 1.5 x 10(9th power)/L

               -  Hemoglobin ≥ 8 g/dL

               -  Platelets ≥ 75 x 10(9th power)/L

               -  Serum total bilirubin ≤ 1.5 x upper limit of normal(ULN), except for patients
                  with Gilbert's syndrome who may be included if total bilirubin ≤ 3.0 x ULN and
                  direct bilirubin ≤ 1.5 x ULN

               -  Aspartate transaminase (AST) < 3.0 x ULN, except for patients with liver
                  metastasis, who are only included if AST < 5 x ULN; alanine transaminase (ALT) <
                  3.0 x ULN, except for patients with liver metastasis, who are only included if
                  ALT < 5 x ULN

               -  Creatinine clearance ≥ 30 mL/min

          -  Patient has following lab values or has lab values corrected with supplements to be
             within normal limits at screening:

               -  Potassium ≥ LLN

               -  Magnesium ≥ LLN

               -  Phosphorus ≥ LLN

               -  Total calcium (corrected for serum albumin) ≥ LLN

        Exclusion Criteria:

          -  Co-morbid condition(s) that prevent safe surgical treatment

          -  Active infection or fever > 38.5°C

          -  Patients with known hypersensitivity to any excipients of ceritinib

          -  Prior therapy with ceritinib

          -  Patients with known history of extensive disseminated bilateral interstitial fibrosis
             or interstitial lung disease, including a history of pneumonitis, hypersensitivity
             pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and clinically
             significant radiation pneumonitis (affecting activities of daily living or requiring
             therapeutic intervention)

          -  Clinically significant uncontrolled heart disease and/or recent cardiac event (within
             6 months), such as:

               -  history of documented congestive heart failure (New York Heart Association
                  functional classification III-IV);

               -  uncontrolled hypertension defined by a Systolic Blood Pressure ≥ 160 mm Hg and/or
                  Diastolic Blood Pressure ≥ 100 mm Hg, with or without antihypertensive medication

               -  initiation or adjustment of antihypertensive medication(s) is allowed prior to
                  screening;

               -  ventricular arrhythmias; supraventricular and nodal arrhythmias not controlled
                  with medication;

               -  other cardiac arrhythmia not controlled with medication;

               -  corrected QTc > 450 msec using Fridericia correction on the screening ECG

          -  Impaired GI function or GI disease that may alter absorption of ceritinib or inability
             to swallow up to five ceritinib capsules daily

          -  Ongoing GI adverse events > grade 2 (e.g. nausea, vomiting, or diarrhea) at the start
             of the study

          -  Receiving medications that meet 1 of the following criteria and cannot be discontinued
             at least 1 week prior to start of treatment with ceritinib and for the duration of
             participation:

               -  Medication with a known risk of prolonging the QT interval or inducing Torsades
                  de Pointes

               -  Strong inhibitors or strong inducers of CYP3A4/5

               -  Medications with a low therapeutic index that are primarily metabolized by
                  CYP3A4/5, CYP2C8 and/or CYP2C9

               -  Therapeutic doses of warfarin sodium (Coumadin) or any other coumadin-derived
                  anti-coagulant. Anticoagulants not derived from warfarin are allowed

          -  Pregnant or nursing (lactating) women.

          -  Women of child-bearing potential, unless they are using highly effective methods of
             contraception during dosing and for 3 months after the last dose of study treatment.